Norepinephrine
|
Basic information |
| Metabolite name | Norepinephrine |
 | HMDB0000216 |
 |
C00547 |
 |
439260 |
| Synonyms | NE; |
| No. of studies | 50 |
|
Basic information |
| Metabolite name | Norepinephrine |
| HMDB0000216 |
|
C00547 |
|
439260 |
| Synonyms | NE; |
| No. of studies | 50 |
|
Relationship between Norepinephrine and depression (count: 50) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M023 | Type2 | CUMS + middle dose of venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M023 | Type2 | CUMS + high dose of venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1005 | Type1 | CUMS group vs. control group | Ileum | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1005 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1005 | Type2 | CUMS + butyrate group vs. CUMS group | Ileum | Sprague-Dawley rat | Up |
| Study M1025 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1026 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1086 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type3 | L-theanine group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M1106 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1106 | Type2 | CUMS + middle dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type2 | CUMS + high dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1126 | Type1 | ovariectomy group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1126 | Type2 | ovariectomy + middle dose of Danggui-Shaoyao-San group vs. ovariectomy group | Hippocampus | Sprague-Dawley rat | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M141 | Type1 | LPS group vs. control group | Prefrontal cortex | ICR mouse | Down |
| Study M141 | Type2 | LPS +high dose of JTW group vs. LPS group | Prefrontal cortex | ICR mouse | Up |
| Study M141 | Type2 | LPS + low dose of JTW group vs. LPS group | Prefrontal cortex | ICR mouse | Up |
| Study M141 | Type2 | LPS + fluoxetine group vs. LPS group | Prefrontal cortex | ICR mouse | Up |
| Study M170 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M170 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M176 | Type1 | CUMS group vs. control group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + middle dose of HCPE group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + low dose of HCPE group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + paroxetine group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M191 | Type1 | CRS group vs. control group | Prefrontal cortex | C57BL/J mouse | Down |
| Study M191 | Type2 | CRS + L-theanine group vs. CRS group | Prefrontal cortex | C57BL/J mouse | Up |
| Study M246 | Type1 | stress group vs. control group | Urine | Tree shrew | Up |
| Study M246 | Type2 | stress + SLV-323 group vs. stress group | Urine | Tree shrew | Down |
| Study M262 | Type1 | stress group vs. control group | Urine | Tree shrew | Up |
| Study M262 | Type2 | stress + SONU group vs. stress group after 2-3 week treatment | Urine | Tree shrew | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M522 | Type2 | CUMS + NaP group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M523 | Type1 | CUMS group vs. control group | Brain | Wistar rat | Down |
| Study M558 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + low dose of polysaccharides group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M559 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M559 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + low dose of volatile oils group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + high dose of terpenoids group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + high dose of volatile oils group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M559 | Type2 | CUMS + low dose of polysaccharides group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M570 | Type1 | CMS group vs. control group | Hippocampus | BALB/c mouse | Up |
| Study M570 | Type1 | CMS group vs. control group | Serum | BALB/c mouse | Down |
| Study M570 | Type1 | CMS group vs. control group | Cerebral cortex | BALB/c mouse | Down |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Hippocampus | Sprague-Dawley rat | Up |
| Study M574 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M581 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M594 | Type1 | CRS group vs. control group | Entorhinal cortex | C57BL/6 mouse | Up |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + high dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M634 | Type1 | CUMS group vs. control group | Cerebrospinal fluid | C57BL/6 mouse | Down |
| Study M634 | Type2 | CUMS + escitalopram group vs. CUMS group | Cerebrospinal fluid | C57BL/6 mouse | Up |
| Study M634 | Type2 | CUMS + PUFA group vs. CUMS group | Cerebrospinal fluid | C57BL/6 mouse | Up |
| Study M650 | Type3 | middle dose of hispidol group vs. hispidol control group, after TST | Brain | ICR mouse | Down |
| Study M650 | Type3 | high dose of hispidol group vs. hispidol control group, after TST | Brain | ICR mouse | Down |
| Study M665 | Type1 | CRS group vs. control group | Hypothalamus | C57BL/6 mouse | Down |
| Study M710 | Type1 | olfactory bulbectomized group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M710 | Type2 | olfactory bulbectomized + low dose of Rhodioloside group vs. olfactory bulbectomized group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M710 | Type2 | olfactory bulbectomized + amitriptyline group vs. olfactory bulbectomized group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M710 | Type2 | olfactory bulbectomized + high dose of Rhodioloside group vs. olfactory bulbectomized group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M711 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M712 | Type1 | depression group vs. control group | Prefrontal cortex | Cynomolgus monkey | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type2 | CUMS + low dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M736 | Type2 | cuff + etifoxine group vs. cuff + vehicle group | Brainstem | C57BL6J mouse | Down |
| Study M758 | Type1 | CUMS group vs. control group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type1 | CUMS group vs. control group | Ventral tegmental area | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M795 | Type1 | gastric cancer + ICI-118,551 + CUMS group vs. gastric cancer + ICI-118,551 group | Plasma | BALB/c nude mouse | Up |
| Study M795 | Type1 | gastric cancer + CUMS group vs. gastric cancer group | Plasma | BALB/c nude mouse | Up |
| Study M816 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M816 | Type2 | CUMS + high dose of Baihe Jizihuang Tang group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M832 | Type3 | dehydrozingerone 1h group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M832 | Type3 | dehydrozingerone 3h group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M832 | Type3 | escitalopram group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M848 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M848 | Type2 | CRS + dexamethasone group vs. CRS group | Serum | C57BL/6 J mouse | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M867 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Urine | Sprague-Dawley rat | Unknown |
| Study M889 | Type1 | CUMS group vs. control group | Serum | BALB/c mouse | Down |
| Study M889 | Type1 | CUMS group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M889 | Type2 | CUMS + high dose of Jiaotai Pills group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + low dose of Jiaotai Pills group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + high dose of Jiaotai Pills group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + low dose of Jiaotai Pills group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M922 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M922 | Type1 | CUMS group vs. control group | Dorsal raphe nucleus | Sprague-Dawley rat | Down |
| Study M922 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M978 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M982 | Type1 | adult MDD group vs. adult control group | Plasma | Human | Up |